Vericel CFO Calls Consensus 'A Pretty Good Starting Point' For 2027, Says Guidance Will Open Cautiously
Management says it is outpacing its long-term revenue target but will start 2027 guidance prudently after lifting this year's outlook to $344 million to $346 million.
Vericel, which makes the MACI knee-cartilage cell therapy and burn-care products, will begin 2027 guidance more conservatively than its internal plans, Chief Financial Officer Joe Mara told analysts on the company's third-quarter earnings call Thursday. Mara said Wall Street's numbers are "probably a pretty good starting point," after the company raised full-year revenue guidance to $344 million to $346 million from $330 million to $340 million.
Consensus as the floor for 2027
A Truist analyst asked whether a 20% growth base for MACI next year was fair. Mara said consensus on total revenue, MACI and, to a degree, burn care is a sound starting point, and that internal expectations are higher. Formal guidance, he said, will "start a little bit more conservatively" than that, because "we just don't want to get ahead of ourselves" in November.
He pointed to this year's pattern. Vericel opened 2026 guiding MACI to similar year-over-year dollar growth, which he called prudent, and then beat it. He said consensus for next year sits in the same place.
On margins, Mara said consensus for gross margin and adjusted EBITDA is also a good starting point. He expects gross margin in the mid-70% range again, with some bottom-line expansion, and said the company is on track to reach a high-30% adjusted EBITDA margin over the next few years.
Ahead of the half-billion target
Asked by a TD Cowen analyst about updating long-range targets, Mara said Vericel is "probably kind of outpacing our expectations" on the path to $500 million in revenue by the end of the decade. He said the company will not update the targets now.
Third-quarter revenue rose 26% to $85.4 million. MACI revenue rose 21% to $67.4 million, and burn care rose 52% to $18 million. Net income climbed 179% to $14.2 million, or 27 cents per diluted share, and adjusted EBITDA rose 48% to $25.2 million, a 30% margin.
This was the third straight quarter of raised revenue guidance, leaving the year $24 million above its starting point. Full-year MACI guidance is now $290 million to $292 million, and adjusted EBITDA margin guidance is about 28%, up from 27%.
What Vericel sells and where it is growing
Vericel makes MACI, built from a patient's own cartilage cells, and Epicel, a skin replacement for severe burns. It also holds North American rights to NexoBrid, which removes dead burn tissue. CEO Nick Colangelo said October was MACI's strongest biopsy month since launch, and that new sales territories lead in biopsy growth. A UK launch of MACI is on track for the second half of 2027.
Vericel ended the quarter with $236 million in cash and investments and no debt. It bought back about 221,000 shares for $8.8 million, leaving $191 million on its repurchase authorization. Colangelo said the company can pursue buybacks and acquisitions at the same time.
For burn care, Mara said Vericel will use a similar framework next year and "probably start a bit prudent there as well."
Sources
- Verical Shares Rise After Higher 3Q Profit, Guidance Increase — MarketWatch
- Vericel beats Q3 street views, raises FY2026 revenue guidance above analyst consensus (VCEL:NASDAQ) — seekingalpha.com
- Vericel Q3 2026 Earnings Call Transcript — benzinga.com
- Vericel (VCEL) Stock Looks Overvalued Given Its Earnings Support — Yahoo Finance
- Motorola Solutions, Sezzle, Unity Software, Toyota Motor And Other Big Stocks Moving Higher On Thursday — benzinga.com